Nanobiotix shares last traded at $39.7310, with a volume of 23,368 shares traded. HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a research report on Monday, May 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research report on Friday, July 17th. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after purchasing an additional 2,500 shares in the last quarter. Nanobiotix Company Profile(Get Free Report)Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment.